science wire

« BACK

Pharmacology



Results 1301 - 1350 of 1869.


Pharmacology - Health - 01.10.2015
Novartis announces NEJM publication of secukinumab Phase III data confirming significant efficacy in patients with psoriatic arthritis
In the FUTURE 1 study, secukinumab showed rapid and significant efficacy in active psoriatic arthritis (PsA) patients, including improvement of skin and joint disease and reduction in progression of joint structural damage Clinical benefits with secukinumab observed in patients with previous treatment with standard of care anti-TNF therapy and those without prior treatment Secukinumab is the first IL-17A inhibitor to report positive Phase III re

Health - Pharmacology - 28.09.2015
Patients with aggressive form of melanoma lived for more than two years on average when taking Novartis therapies Tafinlar + Mekinist
Phase III data showed median overall survival of 25.6 months in patients with BRAF+ V600E/K metastatic melanoma who received Tafinlar + Mekinist Tafinlar + Mekinist combination also demonstrat

Health - Pharmacology - 27.09.2015
Novartis drug Afinitor significantly improves progression-free survival in advanced nonfunctional gastrointestinal and lung NET
In pivotal study, everolimus reduced risk of disease progression by 52%; showed 11.0-month median progression-free survival vs 3.9 months for placebo Advanced, progressive, nonfunctional neuroendocrine tumors of GI or lung origin are rare forms of cancer with poor prognoses and limited treatment options ,[3, RADIANT-4 results highlighted at key European cancer congress; worldwide regulatory filings are underway Basel, September 27,

Health - Pharmacology - 25.09.2015
Novartis' new heart failure medicine Entresto(TM) recommended by CHMP for EU approval
Positive opinion from EU review body puts Entresto on track to be approved for HFrEF patients across Europe likely by year end Entresto was studied in world's largest heart failure trial which was stopped early on strength of results that showed a 20% cut in cardiovascular deaths vs enalapril Every day 10,000 Europeans are diagnosed with heart failure and 15 million already live with the condition, facing a high risk of death and poor quality of

Health - Pharmacology - 24.09.2015
Novartis appoints James E. Bradner, MD as President of the Novartis Institutes for BioMedical Research as Mark Fishman retires
New leader to continue to drive long-term innovation in Novartis research in wide range of therapeutic areas Basel, September 24, 2015 - Novartis announced today that Dr. James (Jay) E.

Pharmacology - Health - 24.09.2015
Antidepressants plus blood-thinners slow down brain cancer
24.09.15 - EPFL scientists have found that combining antidepressants with anticoagulants slows down brain tumors (gliomas) in mice. Gliomas are aggressive brain tumors arising from the brain's supporting glial cells. They account for about a third of all brain tumors, and hold the highest incidence and mortality rate among primary brain cancer patients, creating an urgent need for effective treatments.

Health - Pharmacology - 18.09.2015
Swissmedic approves Novartis' new heart failure medicine Entresto(TM)
Decision by Swiss Health Authority follows US Food and Drug Administration (FDA) approval of Entresto in July, serves as an important reference approval for multiple other health authorities   Entresto is  indicated in Switzerland to reduce the risk of cardiovascular mortality and morbidity in patients with heart failure with reduced ejection fraction   People with heart failure face high risk of death and poor quality of life, with only half al

Life Sciences - Pharmacology - 17.09.2015
A barrier against brain stem cell aging
A barrier against brain stem cell aging
Neural stem cells generate new neurons throughout life in the mammalian brain. However, with advancing age the potential for regeneration in the brain dramatically declines. Scientists of the University of Zurich now identified a novel mechanism of how neural stem cells stay relatively free of aging-induced damage.

Life Sciences - Pharmacology - 08.09.2015
Molecular bodyguards for immature membrane proteins
Molecular bodyguards for immature membrane proteins
During their formation within the cells, many proteins rely on the assistance of protectors, so-called chaperones. They help the proteins to fold correctly and thus ensure the right final structure. The roles of chaperones in membrane protein folding have long remained unclear. Researchers at the Biozentrum, University of Basel, and at ETH Zurich now show how chaperones stabilize an immature bacterial membrane protein and guide it in the right folding direction, thus protecting it from misfolding.

Life Sciences - Pharmacology - 07.09.2015
Molecular Bodyguards for Immature Membrane Proteins
Molecular Bodyguards for Immature Membrane Proteins
During their formation within the cells, many proteins rely on the assistance of molecular protectors, so-called chaperones. They help the proteins to fold correctly and thus ensure the right final structure. The roles of chaperones in membrane protein folding have long remained unclear. Researchers at the Biozentrum, University of Basel, and at ETH Zurich have now shown how chaperones stabilize an immature bacterial membrane protein and guide it in the right folding direction, thus protecting it from misfolding.

Health - Pharmacology - 04.09.2015
Novartis receives EU approval for Farydak , the first in its class of anticancer agents approved for patients with multiple myeloma
Farydak (panobinostat) combination is approved in the EU for patients with multiple myeloma who received >= 2 prior regimens including bortezomib and IMiD In clinical trials, Farydak combination i

Pharmacology - Health - 03.09.2015
Sandoz launches ZarxioTM (filgrastim-sndz), the first biosimilar in the United States
Launch follows March 6, 2015 FDA approval Sandoz One Source TM offers patient support services The digital press release with multimedia content can be accessed here:   Holzkirchen, September 3, 2015 - Sandoz, a Novartis company, announced today that Zarxio(TM) (filgrastim-sndz) is now available in the United States.

Health - Pharmacology - 02.09.2015
Novartis receives EU approval for new Revolade use as first-in-class therapy for patients with severe aplastic anemia
Revolade is the first approved therapy in the EU for patients with severe aplastic anemia (SAA) who have not responded to other treatments   Patients living with SAA, a rare blood disorder, have limi

Pharmacology - Physics - 02.09.2015
Preventing crystallization to improve drug efficiency
Preventing crystallization to improve drug efficiency
02.09.15 - Esther Amstad and an international team of researchers have developed a method to increase the solubility of poorly soluble substances, such as many of the newly developed drugs. "Each year, pharmaceutical companies refuse many drugs during early stages of their development because of their poor solubility in the body which prevents their efficient uptake by the human body" explains Esther Amstad.

Pharmacology - Health - 01.09.2015
Novartis announces global partnership with Amgen to develop and commercialize pioneering neuroscience treatments
The companies plan to co-develop and co-commercialize a BACE inhibitor program in Alzheimer's Disease (AD); Novartis' oral therapy CNP520 will be the lead molecule   Novartis and Amgen also plan to c

Health - Pharmacology - 01.09.2015
Novartis receives EU approval for Tafinlar and Mekinist , first combination approved for patients with aggressive form of melanoma
Approval based on two Phase III studies demonstrating statistically significant overall survival benefit with combination therapy vs BRAF inhibitor monotherapy   Targeted combination offers BRAF V600

Health - Pharmacology - 28.08.2015
Novartis continues commitment to go the last mile in effort to eliminate leprosy
New five-year commitment includes donation of treatments worth more than USD 40 million and is expected to reach an estimated 1.3 million patients Novartis Foundation's new leprosy tracing pro

Health - Pharmacology - 24.08.2015
FDA expands use of Novartis drug Promacta to include treatment of children ages 1 and older with chronic immune thrombocytopenia
New oral suspension formulation, designed for younger children with rare blood disorder, is now approved   For about one in four children with ITP, the condition persists for more than 12 months afte

Pharmacology - Health - 21.08.2015
Novartis acquires all remaining rights to GSK's Ofatumumab to develop treatments for MS and other autoimmune indications
Novartis strengthens multiple sclerosis focus with the addition of Ofatumumab to leading MS portfolio which includes Gilenya and investigational treatments BAF312 and CJM112 Ofatumumab is a fully hum

Pharmacology - Health - 20.08.2015
Novartis drug Odomzo gains EU approval for locally advanced basal cell carcinoma, providing new non-invasive therapy for patients
Approval follows positive CHMP opinion based on pivotal Phase II study showing durable objective response rate per central review of 56% in patients with laBCC   Basal cell carcinoma is the most comm

Pharmacology - Health - 17.08.2015
Pivotal Phase II study showed Roche’s investigational immunotherapy atezolizumab shrank tumours in people with a specific type of lung cancer
Pivotal Phase II study showed Roche's investigational immunotherapy atezolizumab shrank tumours in people with a specific type of lung cancer Roche will discuss results with the U.S. Food and Drug Administration (FDA) as part of atezolizumab's Breakthrough Therapy Designation in lung cancer Roche today announced that in the large pivotal Phase II study, BIRCH, the investigational cancer immunotherapy atezolizumab (MPDL3280A; anti-P

Pharmacology - Health - 29.07.2015
Novartis partners with Phase 4 Partners and institutional investors to help create Mereo BioPharma Group Ltd
Novartis is spinning off three mid stage clinical assets to Mereo for further development in exchange for equity Novartis will have a stake in the success of the development of these compounds, inclu

Health - Pharmacology - 28.07.2015
Stress Hormone Reduces Heroin Cravings
Every addiction is characterized by a strong desire for a certain addictive substance, be it nicotine, alcohol or other drug. Researchers at the University of Basel recently conducted a study on heroin addiction and demonstrated that the stress hormone cortisol can reduce addictive cravings. The findings from the research have been published in the medical journal Translational Psychiatry.

Pharmacology - Health - 24.07.2015
FDA approves Novartis drug Odomzo (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer
Approval is based on pivotal Phase II study in which objective response rate (ORR) in patients with laBCC was 58%; responses were durable   Basal cell carcinoma, the most common form of skin cancer,

Health - Pharmacology - 24.07.2015
Novartis drug Revolade recommended by CHMP for EU approval to treat patients with severe aplastic anemia, a serious blood disorder
If approved, Revolade would be the first treatment option in its class in the EU for certain patients with SAA   Approximately 40% of SAA patients unresponsive to initial immunosuppressive therapy (I

Health - Pharmacology - 24.07.2015
Novartis combination therapy Tafinlar and Mekinist achieves important EU and US regulatory milestones
CHMP positive opinion for EU approval of Tafinlar and Mekinist combination in BRAF V600 mutation-positive melanoma, the most aggressive type of skin cancer   FDA grants priority review for full appro

Pharmacology - Economics / Business - 21.07.2015
Novartis delivered solid performance in the second quarter, with strong innovation and progress on new launches
Sales , core operating income and core EPS grew (cc ) for continuing operations in Q2: Net sales amounted to USD 12.7 billion (-5%, +6% cc) Operating income was USD 2.3 billion (-28%,

Pharmacology - Health - 16.07.2015
Novartis malaria treatment Coartem 80/480mg receives WHO prequalification, enabling greater access for patients
WHO prequalified Coartem 80/480mg is the first and only  high strength malaria treatment available for donor-funded public sector procurement   Coartem 80/480mg reduces the pill burden for patients,

Health - Pharmacology - 13.07.2015
In a pivotal study, Roche’s investigational immunotherapy atezolizumab shrank tumours in people with a specific type of bladder cancer
In a pivotal study, Roche's investigational immunotherapy atezolizumab shrank tumours in people with a specific type of bladder cancer Results showed that high levels of PD-L1 expression were associated with greater responses to atezolizumab Roche will discuss results with the U.S. Food and Drug Administration (FDA) as part of atezolizumab's Breakthrough Therapy Designation in bladder cancer Roche today announced that in the IMvigo

Pharmacology - Health - 07.07.2015
Novartis' new heart failure medicine LCZ696, now called Entresto(TM), approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization
Novartis' new heart failure medicine LCZ696, now called Entresto(TM), approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization First in the world approval brings

Pharmacology - Innovation - 30.06.2015
Novartis Pharmaceuticals launches the first app for visually impaired people for use with the Apple Watch and other smart watches
New features of the ViaOpta apps, previously available for iPhone and Android TM mobile phones, are also available to enhance the daily lives of people with visual impairments   These apps foster ind

Pharmacology - Health - 29.06.2015
Novartis announces publication in The Lancet showing sustained efficacy with secukinumab over one year in psoriatic arthritis patients
In the FUTURE 2 study, secukinumab demonstrated rapid onset of action, was significantly superior to placebo in improving signs and symptoms of psoriatic arthritis (PsA), with efficacy sustained over one year   Secukinumab is the first IL-17A inhibitor to significantly improve joint and skin symptoms of PsA, and provides physical functioning and quality of life benefits Global regulatory submissions have been filed for secukinumab in PsA and ank

Pharmacology - Life Sciences - 29.06.2015
Novartis deepens its industry leading pipeline with acquisition of Spinifex Pharmaceuticals, Inc
Acquisition adds novel angiotensin II Type 2 receptor antagonist for the treatment of neuropathic pain to Novartis' industry-leading development pipeline    Neuropathic pain is a chronic condition wi

Health - Pharmacology - 26.06.2015
Novartis drug Farydak recommended by CHMP for EU approval to treat multiple myeloma, providing patients a new mechanism of action
Farydak (panobinostat) combination improved PFS by 7.8 months for patients who received >=2 prior regimens including bortezomib and an IMiD Farydak would be the first HDAC inhibitor with ep

Pharmacology - Health - 18.06.2015
Sandoz announces US launch of Glatopa(TM), the first generic competitor to Copaxone 20mg
Glatopa is the first FDA-approved, substitutable generic version of Copaxone   20mg, a treatment for relapsing forms of multiple sclerosis Sandoz has begun shipping to US customers following recent F

Pharmacology - Health - 18.06.2015
Novartis highlights strong innovation momentum at its second Meet Novartis Management investor day
Strong progress on innovation across divisions Pharmaceuticals is building breadth and depth in seven franchises, including Oncology, where it is complementing leadership in targeted therapies and CA

Health - Pharmacology - 13.06.2015
Novartis presents new data from large European study reinforcing the benefit of first-line Tasigna in newly-diagnosed patients with CML
Patients on Tasigna achieved rapid and high rates of molecular response with a very low rate of progression to advanced disease   ENEST1st data confirm the favorable benefit/risk profile of Tasigna in newly-diagnosed CML patients seen in the pivotal ENESTnd study   Safety results in this Phase 3b study of more than 1,000 European patients were consistent with the known safety profile of Tasigna - Novartis today announced results from the Phase 3

Health - Pharmacology - 02.06.2015
Novartis presents new data at EULAR and WCD further demonstrating its leadership in severe long-term inflammatory and skin conditions
New one-year data for secukinumab, the first IL-17A inhibitor to show significant improvement in ankylosing spondylitis (AS) signs and symptoms, to be presented at European League Against Rheumatism meeting (EULAR) Cosentyx (TM) (secukinumab) data to be revealed in patients with difficult-to-treat psoriasis of the palms, soles and nails at World Congress of Dermatology (WCD) Late-breaking results at WCD include the impact of Xolair (omalizumab)

Pharmacology - Health - 01.06.2015
Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma
Data show adult patients may achieve durable response rates, with 13 of 19 evaluable patients with relapsed/refractory non-Hodgkin lymphomas responding to therapy   Recent milestones for Novartis CAR therapy program include initiation of global Phase II multi-center CTL019 study and activation of cell processing facility   Data also highlight preliminary safety and efficacy data for CTL019 in other indications                Basel, Switzerland,

Health - Pharmacology - 01.06.2015
Novartis presents new data at ASCO for Zykadia and combination of Tafinlar and Mekinist in certain NSCLC patients with unmet needs
In Phase II studies, Zykadia (ceritinib) shrank tumors in patients with ALK+ NSCLC; comparable overall response in those with or without brain metastases ,   Tafinlar (dabrafenib) and Mekinist (trame

Health - Pharmacology - 31.05.2015
Combination of Novartis drugs Tafinlar and Mekinist shows significant survival benefit in patients with metastatic melanoma
Final analysis of COMBI-d confirms overall survival benefit of combination therapy in patients with BRAF V600E/K mutation-positive metastatic melanoma   Tafinlar and Mekinist in combination achieved

Health - Pharmacology - 21.05.2015
Novartis drug Afinitor extended progression-free survival in Phase III trial in advanced gastrointestinal or lung neuroendocrine tumors
Study in patients with advanced nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin met primary endpoint   Full results will be submitted for presentation at a major med

Pharmacology - Health - 20.05.2015
Novartis announces two positive US phase III programs in COPD for QVA149 and NVA237
QVA149 improved lung function, breathlessness and health-related quality of life in moderate-to-severe COPD patients, according to EXPEDITION trial results -   GEM 1 & 2 studies showed NVA237 pro

Health - Pharmacology - 08.05.2015
Novartis lung cancer drug Zykadia gains EU approval, providing new therapy for certain patients with ALK+ NSCLC
Zykadia (ceritinib) is the first treatment option approved for patients in Europe with ALK+ NSCLC previously treated with the ALK inhibitor crizotinib   Marketing authorization was based on two studi

Health - Pharmacology - 27.04.2015
Novartis announces Phase III study of Arzerra met primary endpoint of improved progression-free survival in patients with relapsed CLL
Positive top-line results seen with Arzerra plus fludarabine and cyclophosphamide in chronic lymphocytic leukemia (CLL) patients when initial treatment stopped working   CLL is the most commonly diag

Pharmacology - Economics / Business - 23.04.2015
Novartis delivered sales growth (cc), significant margin expansion (cc) and strong innovation in Q1[1]; now with a more focused portfolio
Continuing operations saw sales, core operating income and core EPS grow (cc ) in Q1 Net sales were USD 11.9 billion (-7%, +3% cc) Operating income was USD 2.8 billion (-1%, +15% cc) Cor

Health - Pharmacology - 21.04.2015
Data at AAN showed Gilenya high efficacy in achieving ’no evidence of disease activity’ in previously-treated highly-active MS patients
Data at AAN showed Gilenya high efficacy in achieving 'no evidence of disease activity' in previously-treated highly-active MS patients New FREEDOMS/FREEDOMS II sub-group analysis showed Gilenya-treated patients were six-times more likely to achieve 'no evidence of disease activity  (NEDA4)' vs placebo NEDA4 is based on four key measures of relapsing MS (RMS): relapses, MRI lesions, MS-related brain shrinkage and disability progression Separate

Pharmacology - Health - 16.04.2015
Sandoz receives FDA approval for GlatopaTM as the first generic competitor to MS therapy Copaxone 20mg
Glatopa is the first FDA-approved, substitutable generic version of Copaxone   20mg, a treatment for relapsing forms of multiple sclerosis Novartis and Sandoz are driving access to a full range of di

This site uses cookies and analysis tools to improve the usability of the site. More information. |